The iRGD peptide specifically binds to integrin αvβ3 and neuropilin-1 (Nrp1) receptors overexpressed on tumor cells, leading to a 2.3-fold increase in cellular uptake in MDA-MB231 breast cancer cells. This evidence concerns the gene NRP1 and breast carcinoma.